Aquestive Therapeutics (AQST) FCF Margin (2017 - 2026)
Aquestive Therapeutics' (AQST) quarterly FCF Margin came in at 102.85% in Q1 2026, up 16704.0% year-on-year from N/an in Q1 2025, and down 491.15% quarter-over-quarter from 26.29% in Q4 2025.
Aquestive Therapeutics (AQST) FCF Margin (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' FCF Margin history runs 10 years deep, the most recent figure standing at 102.85% for Q1 2026.
- On a quarterly basis, FCF Margin rose 16704.0% year-over-year to 102.85% in Q1 2026; TTM through Mar 2026 was 657.37%, a 56693.0% decrease from a year earlier, with the FY2025 full-year figure at 5595.31%, down 553291.0% from the prior year.
- FCF Margin slipped to 102.85% in Q1 2026 per AQST's latest filing, from 26.29% in the prior quarter.
- Across five years, FCF Margin topped out at 79.16% in Q1 2023 and bottomed at 269.9% in Q1 2025.
- The 5-year median for FCF Margin is 65.95% (2023), against an average of 55.06%.
- Across the five-year window, FCF Margin jumped 19804 bps in 2023 and plunged 18350 bps in 2025, its largest moves.
- Year by year, FCF Margin stood at 78.54% in 2022, then tumbled by 138 bps to 30.01% in 2023, then sank by 87 bps to 56.02% in 2024, then jumped by 147 bps to 26.29% in 2025, then tumbled by 491 bps to 102.85% in 2026.
- Per Business Quant, the three latest AQST FCF Margin figures stand at 102.85% (Q1 2026), 26.29% (Q4 2025), and 101.84% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -5.22% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 12.86% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -5.35% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 46.54% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 9.93% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 17.73% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.77% |
| 10 | Aquestive Therapeutics | 462.24 Mn | 462.24 Mn | 13.47 Mn | -102.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -102.85% |
| Dec 31, 2025 | 26.29% |
| Sep 30, 2025 | -101.84% |
| Jun 30, 2025 | -78.60% |
| Mar 31, 2025 | -269.90% |
| Dec 31, 2024 | -56.02% |
| Sep 30, 2024 | -87.73% |
| Jun 30, 2024 | -34.71% |
| Mar 31, 2024 | -86.39% |
| Dec 31, 2023 | -30.01% |
| Sep 30, 2023 | -19.21% |
| Jun 30, 2023 | -65.95% |
| Mar 31, 2023 | 79.16% |
| Dec 31, 2022 | 78.54% |
| Sep 30, 2022 | 22.61% |
| Jun 30, 2022 | -90.49% |
| Mar 31, 2022 | -118.88% |
| Dec 31, 2021 | -77.58% |
| Sep 30, 2021 | -68.85% |
| Jun 30, 2021 | -97.50% |